Cholangiocarcinoma and pancreatic head cancer are still linked with extremely high 5-year mortality in the western world. Th e management of such patients is complex and typically requires a multidisciplinary approach in a tertiary care center. Interventional radiology off ers minimally invasive, image-guided treatment for a variety of diseases and conditions. Regarding patients with malignant biliary obstruction, IR options are considered for more than two decades as a valid management tool for both operable and non-operable cases. Th e options include placement of percutaneous transhepatic biliary drains, preoperative embolization of the portal vein and deployment of covered and uncovered biliary stents. Th e purpose of this review is to describe the current evidence in this continuously evolving fi eld.
Introduction
Malignant jaundice occurs when there is a blockage of the biliary tree, either by direct tumor infi ltration or by external compression. Th e underlying malignancies in the vast majority of cases are cholangiocarcinoma and adenocarcinoma of the pancreatic head [1] . Other tumors of the area may be gallbladder or gastric cancer, intrahepatic metastases or metastatic hilar lymph nodes. In all cases, dilatation of the biliary ducts occurs and the bile is prevented from fl owing towards the duodenum. Th e main presentation symptom is jaundice, however in some cases of advanced disease cholangitis and sepsis may also occur. Th e management of such patients typically requires a multidisciplinary setting in a tertiary care center, involving gastroenterologists, hepato-pancreato biliary surgeons, oncologists and radiologists. Th e purpose of this review is to describe the role of interventional radiology (IR) in the management of such complex patients.
Management of patients with malignant biliary obstruction
Th e fi rst-line imaging examination for patients presenting with jaundice is usually an abdominal ultrasound (US) scan that confi rms the dilatation of the biliary ducts; US is usually followed by cross sectional imaging that may be either computed tomography or magnetic resonance imaging to delineate the nature of the occlusion (benign or malignant). When a suspicious lesion is confi rmed the next step will be to obtain tissue diagnosis. Th is is usually feasible with endoscopic US (EUS) guidance and fi ne needle aspiration of cells from the lesion. Th e multidisciplinary meeting will decide on the stage the disease and defi ne weather the lesion may be excised surgically or not. IR has an important role in both operable and non-operable lesions. levels of bilirubin and of liver function are required. In such cases, placement of a percutaneous transhepatic external biliary drain is considered as the best option. Th e drain needs to be external only to limit the risk of ascending cholangitis that may jeopardize surgical treatment.
A percutaneous transhepatic cholangiogram is usually performed with the use of a 21G needle system, preferably under US guidance. Once access in the biliary tree is obtained, contrast injection under fl uoroscopy delineates the level of the occlusion. Th en a 0.021" microwire is advanced through the 21G needle into the biliary tree and over this a 0.035" coaxial system is advanced; the 0.021" microwire is then exchanged for a 0.035" glidewire usually of the stiff type. Further contrast injection may follow at this stage if the patient is not septic. If the patient is septic, contrast injection needs to be very limited due to the risk of septicemia. Th en, over the 0.035" guidewire, a multihole all-purpose locking pigtail drain catheter is inserted and connected to an external bag (Fig. 1A) . Th e drain needs to be fi xed to the skin as it may easily be dislodged. If histology under EUS guidance is not feasible, a transbiliary biopsy may also be obtained from the transhepatic access prior to drain insertion (Fig. 1B) .
Percutaneous transhepatic biliary drainage may lead to complications such as bleeding, sepsis, peritonitis and bile leak. Procedure-related death is reported between 0.6-5.6% [2] [3] [4] [5] . Th e British Society of Interventional Radiology (BSIR) published a registry in 2011 [6] , in which factors responsible for increased mortality of the procedure were noted. Th e registry included 610 patients who received percutaneous biliary drainage for malignant biliary obstruction. Th e total mortality reported was 19.8% (121/610), mainly attributed to the presence of ascites, advanced disease status and the poor general conditions of the patients included in the registry. However, another factor was that not all cases were performed is tertiary care specialist centers. In the eff ort to perform a risk stratifi cation analysis Tapping et al [7] published their experience on 704 patients with obstructive jaundice who received percutaneous transhepatic biliary drainage over a 7-year period and concluded that a scoring system using mainly the following factors: high white cell count; high C-reactive protein; low hemoglobin; and high bilirubin may be a reliable predictor of complications and mortality. In this study performed in a tertiary care center the procedure-related mortality rate was 2%.
Portal vein embolization (PVE)
In case of large lesions, where a signifi cant percentage of the liver parenchyma needs to be excised, PVE may be considered as necessary in addition to the drainage of the bile ducts. Th e embolization of the portal vein induces hypertrophy of the contralateral liver lobe to achieve a satisfactory residual percentage of liver parenchyma post-excision. Technically, PVE is performed aft er percutaneous US-guided access to the portal system. Usually a 21G needle is used as described for the biliary tree access, and then the system is upsized to 0.035". Embolization may be performed with the use of coils, plugs, particles or histoacryl glue [8] (Fig. 2) . PVE and drainage may be performed in a sequential approach as a two-stage procedure or as recently published study by Guiu et al [9] during the same session.
The role of IR in the management of non-operable lesions
In non-operable lesions palliation is required with the use of stents. Drainage of the biliary tree is of paramount importance for the quality of life of the oncologic patients as normal liver function is required for the administration of chemotherapy [10] . Prior to the era of cross-sectional imaging, palliation is such cases was historically performed surgically through an exploratory laparotomy which, among others, was necessary to defi ne the stage of disease. However, for more than two decades accurate staging is now performed with cross sectional imaging and such patients are treated with the use of stents inserted either endoscopically or percutaneously [11, 12] . 
Bare stents
Bare self-expandable metallic stents (SEMS) were introduced in the clinical practice more than 25 years ago. Th ey were mainly developed to overcome problems of the initially used plastic stents. Th e main problem of plastic stents was their relative small lumen. Th e size of plastic stents is limited to 12Fr when placed endoscopically (this is the maximum size that may fi t though the accessory channel of the endoscope), or to 14Fr when placed percutaneously, whereby the created large intrahepatic tract can be challenging to seal. On the other hand, SEMS are typically mounted over a 6 or 7Fr carrying catheter, however they reach a lumen of up to 30 Fr when deployed. Th is way, SEMS off er signifi cantly longer patency times than plastic stents [13, 14] . Th e initial cost of SEMS was signifi cantly higher than the cost of the plastic stents, however their placement was considered as cost-eff ective due to the longer patency [15] . More recent studies have confi rmed the results of the mid 90's. In particular, two systematic reviews confi rm that that SEMS are less likely to get occluded compared to plastic stents without signifi cant diff erence on technical failure, complication rate and mortality [16, 17] . Th e superiority of SEMS over plastic ones is also confi rmed in two recently published randomized controlled trials and a metaanalysis [18] [19] [20] .
Bare SEMS are made from either stainless steel or nitinol and are formed from a mesh placed in a tubular fashion. Th e fact that a mesh is used permits to the endoprosthesis to be embedded into the biliary wall [21] and diminishes the risk of migration. However, within the next six months, neoplastic tissue is growing through the mesh of the stent (ingrowth) and the endoprosthesis gets occluded, thereby requiring an additional stent to be deployed. Th e rate of this process has been reported in the range of 20-50% [13] [14] [15] 22] . In order to limit ingrowth, covered biliary stents were developed.
Covered biliary stents
Covered biliary stents are also made from a tubular mesh, however, this is covered by a thin membrane [23] [24] [25] [26] [27] [28] . Covered stents are not integrated within the biliary wall and can be removed if so required. Th is is also a disadvantage because migration may occur. Th erefore covered stents with anti-migrational mechanism were designed and integrated in the clinical practice [29] [30] [31] . Th e covering material may be polyurethane, silicone or ePTFE/FEP. Th e latter has shown satisfactory results in preventing from tumor ingrowth [32] . Th ere are some technical limitations in the deployment of covered stents in relation with the location of the cystic duct that should not be covered by the membrane in order to avoid cholecystitis (Fig. 3) . Th erefore, a measuring pigtail needs to be used in order to measure the exact length of the lesion prior to deployment of a covered stent. Th e carrying catheter of the covered stents is usually larger (10Fr) than the one of the bare stents (6-7Fr).
Hilar lesions
For hilar lesions (Bismuth types III and IV) bilateral access and simultaneous deployment of two stents is required in a "Y" confi guration. Th e stents used in such occasions are usually bare, however covered stents may also be used as far as the cystic duct is not obstructed. In case bilateral access is not feasible, then bare stents in a "7" confi guration is suggested. Th ere are specifi cally designed stents with less dense struts in the central portion that permit the insertion of another stent through their mesh.
Endobiliary radiofrequency ablation (RFA)
RFA is an established method of tumor treatment based on high frequency rapidly alternating electric current [33, 34] . Th e energy is usually delivered through an electrode that is placed under imaging guidance in the tumoral tissue. Th ere has been a lot of interest lately on the use of biliary intraductal RFA devices initially in animal experiments and then in patients with non-resectable pancreatic head adenocarcinoma or cholangiocarcinoma [35, 36] . In the initial studies the device used was placed endoscopically, however in the study of Mizandari et al [37] the authors describe a percutaneous transhepatic placement in 39 patients with malignant biliary stricture. In all patients, a bare metallic stent was deployed in the stenotic area postablation without major complications. However, long-term results are required to evaluate further this innovative technique.
Concluding remark
IR off ers a valid minimally invasive therapeutic option for both operable and non-operable cases with malignant biliary obstruction and plays a signifi cant role in the management of such patients in a tertiary care multidisciplinary setting. 
